

Supplemental Approvals

Generic Name (Trade Name—Company)

August 20, 2018

Pembrolizumab

(Keytruda—Merck)

Pembrolizumab approved in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC

Uses/Notes

[FDA approved](#) pembrolizumab in combination with pemetrexed and platinum as first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer (NSqNSCLC), with no EGFR or ALK genomic tumor aberrations.

Approval was based on the results of KEYNOTE-189, a randomized, multicenter, double-blind, active controlled study enrolling 616 patients receiving first-line treatment for metastatic NSqNSCLC. The trial demonstrated a statistically significant improvement in overall survival for patients randomized to pembrolizumab and chemotherapy in a prespecified interim analysis.

The most common adverse reactions were fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, and pyrexia.

The recommended pembrolizumab dose and schedule for this indication is 200 mg as an I.V. infusion over 30 minutes every 3 weeks.

Source URL:

<http://aphanet.org/supplemental-approvals/pembrolizumab-approved-combination-chemotherapy-first-line-treatment>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.